NasdaqGS:PRAXBiotechs
A Look At Praxis Precision Medicines (PRAX) Valuation As Late Stage Epilepsy Plans Move Toward FDA Filings
Praxis Precision Medicines (PRAX) is in focus after management outlined plans to file two New Drug Applications with the FDA by mid February 2026, alongside appointing epilepsy expert Dr. Orrin Devinsky as Head of Clinical Strategy.
See our latest analysis for Praxis Precision Medicines.
The latest clinical updates and leadership changes come against a backdrop of sharp price swings, with a 90 day share price return of 79.17% and a very large 1 year total shareholder return of 304.24%, while...